ScreenerHero

IRLAB-A IRLAB Therapeutics AB (publ)

STO · SE · Healthcare · Biotechnology · irlab.se
1.820SEK+0.89%Mkt Cap: 25.89M $P/E: —

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which ha…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
INSM
Insmed Incorporated
$22.98BUSD
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap25.89M USD
Enterprise Value25.44M USD
Revenue (TTM)7.59M USD
Gross Profit75.28K USD
Net Income (TTM)-10.52M USD
Revenue/Share0.95 SEK
Last Price1.820 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees31
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.28
PEG—
EV/EBITDA-7.01
EV/Revenue3.35
P/S3.48
P/B2.84
EPS (TTM)-0.64
EPS (Forward)-0.13
52W Range
1.17034% of range3.075
52W High3.075 SEK
52W Low1.170 SEK
Profitability
Gross Margin0.99%
Oper. Margin-260.85%
EBITDA Margin-47.83%
Profit Margin-191.45%
ROE-358.13%
ROA-78.13%
Growth
Revenue Growth-67.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.28M USD
CapEx (TTM)—
FCF Margin-155.23%
FCF Yield-45.50%
Net Debt-958.15K USD
Net Debt/EBITDA0.26
Balance Sheet
Debt/Equity0.98
Current Ratio1.55
Quick Ratio1.55
Book Value/Sh0.65 SEK
Cash/Share0.23 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 SEK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split5:1
Split DateMay 28, 2019
Analyst Consensus
Rating—
Target (Mean)7.500 SEK
Upside (mean)+312.1%
Target Range7.500 SEK – 7.500 SEK
# Analysts1
Ownership
Shares Out.148.63M
Float122.25M
Insiders16.27%
Institutions23.57%
Technical
SMA 501.669 (+9.0%)
SMA 2001.561 (+16.6%)
Beta0.56
S&P 52W Chg14.58%
Avg Vol (30d)1.04M
Avg Vol (10d)738.07K
Technical Indicators
RSI (14)55.0
MACD0.0400
MACD Signal0.0504
MACD Hist.-0.0104
BB Upper1.933 SEK
BB Middle1.822 SEK
BB Lower1.711 SEK
BB Width12.23%
ATR (14)0.0964 SEK
Vol Ratio (20d)0.42x